granisetron and sertraline

granisetron has been researched along with sertraline in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Eftekhar Ardebili, M; Ghobadian, A; Kamalzadeh, L; Mokhtari, S; Shalbafan, M; Shariati, B; Shati, M; Yarahmadi, M	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

1 review(s) available for granisetron and sertraline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for granisetron and sertraline

Article	Year
Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. BMC pharmacology & toxicology, 2022, 09-27, Volume: 23, Issue:1 Topics: Double-Blind Method; Drug Therapy, Combination; Granisetron; Humans; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Treatment Outcome	2022

Article

Year

Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.

BMC pharmacology & toxicology, 2022, 09-27, Volume: 23, Issue:1

Topics: Double-Blind Method; Drug Therapy, Combination; Granisetron; Humans; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Treatment Outcome

2022

Other Studies

2 other study(ies) available for granisetron and sertraline

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010